SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 26th, 2020 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of 24, 2020, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd.Placement Agent Ordinary Share Purchase Warrant • February 26th, 2020 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on February 24, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ of the Company’s Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, dated as of January 29, 2020, by and between the Company and H.C. Wainwright & Co., LLC.
